Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Søren Østergaard

Henrik Sune Andersen

Patrick William Garibay

Thomas Kruse

Bernd Peschke

Carsten Behrens

Nils Langeland Johansen

Jes Thorn Clausen

Henning Thøgersen

Lauge Schäffer

Jesper Pass

Sonja Bak

Steffen Runge

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Conjugated proteins with prolonged in vivo efficacy

Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.

Anti-human interleukin-20 antibodies

Growing community of inventors

Brønshøj, Denmark

Søren Østergaard